RBR-2z5t7z招募中1 期
Shining Light on COVID-19 - : Shining Light on COVID-19
Anhembi Morumbi0 个研究点开始时间: 2020年11月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 60Y 至 80Y（—）
入选标准
- •The research will include patients: aged between 60 and 80 years; with clinical diagnosis of SARS-Cov-2; undergoing medical treatment at Santa Casa de Pindamonhangaba and Itajubá; in invasive mechanical ventilation and in drug treatment.
排除标准
- •Patients will not be part of the research: institutionalized; overweight (Body Mass Index - BMI: above 29.9 kg / m2); without the signature of the person responsible for the IC; do not belong to the mentioned age group; who have neoplasms and a history of photosensitivity.
研究者
相似试验
尚未招募
4 期
EbolaCovPACTR202407764378004niversity of Birmingham72
已完成
不适用
A low risk, open label, interventional Proof of Concept study to compare data collected simultaneously from S-patch and Holter ambulatory ECG devices fitted to patients with heart arrhythmia.ACTRN12618000215224Counties Manukau Health90
终止
1 期
A Phase I clinical study to evaluate safety, tolerability and biological activity of platelet-derived extracellular vesicles on wound healing in healthy adultsWound healingSkin - Normal skin development and functionACTRN12619001378112Exopharm Ltd3
进行中（未招募）
1 期
Open label, First in human study for CX-2009 in adults with metastatic or locally advanced unresectable solid tumorsEUCTR2017-000625-12-DECytomX Therapeutics, Inc195
进行中（未招募）
1 期
Open label, First in human study for CX-2009 in adults with metastatic or locally advanced unresectable solid tumorsEUCTR2017-000625-12-NLCytomX Therapeutics, Inc563